<DOC>
	<DOCNO>NCT01813422</DOCNO>
	<brief_summary>This study evaluate whether low-density lipoprotein ( LDL-C ) lower Evolocumab ( AMG 145 ) result great change baseline percent atheroma volume ( PAV ) week 78 placebo subject coronary artery disease take lipid lower therapy .</brief_summary>
	<brief_title>GLobal Assessment Plaque reGression With PCSK9 antibOdy Measured intraVascular Ultrasound</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Clinical indication coronary angiography Subjects already take statin therapy , niacin ezetimibe screen must stable dose least 4 week prior screen LDLC . Subjects take lipidregulating therapy must enter study via lipid stabilization period . Subjects intolerant statin must meet statin intolerance entry criterion Fasting LDLC ≥ 80 mg/dL ( 2.07 mmol/L ) without additional risk factor , , LDLC ≥ 60 &lt; 80 mg/dL ( 1.552.07 mmol/L ) presence one major three minor risk factor Subjects must meet follow criterion qualify coronary catheterization procedure : Evidence coronary heart disease ( least one lesion native coronary artery &gt; 20 % reduction lumen diameter ) prior PCI Left main coronary artery &lt; 50 % reduction lumen diameter visual estimation Target Coronary Artery IVUS must accessible IVUS catheter , must &gt; 50 % reduction lumen diameter within target segment ( least 40mm length ) ; undergone prior PCI CABG candidate intervention next 18 month . It may bypass graft , bypass vessel culprit vessel previous MI . Coronary artery bypass graft surgery &lt; 6 week prior qualify IVUS NYHA III IV heart failure , last known leave ventricular ejection fraction le 30 % Uncontrolled cardiac arrhythmia control medication 3 month prior randomization Known hemorrhagic stroke Uncontrolled hypertension randomization Fasting Triglycerides ≥ 400 mg/dL ( 4.5 mmol/L ) screen Type 1 diabetes poorly control type 2 diabetes ( HbA1c &gt; 9 % ) screening . Moderate severe renal dysfunction ( eGFR &lt; 30 ml/min/1.73m2 ) screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>Raised Cholesterol</keyword>
</DOC>